EXHIBIT 52

ACTAVIS TOTOWA LLC.

IN - PROCESS DISPOSITION FORM

PRODUCT: Digoxin Tablets, USP 0.25mg

STAGE : FINAL BLEND BATCH. NO: 70670A

DISPOSITION: RELEASE

RETEST DATE: 09/09/07

COMMENTS: DRUM # 1 To 5

DISPOSITIONED BY: M. GR DATE: 08/22/07

EXHIBIT
Plaintiff's
52
4/27/09 KG
ENGAD 800-631-6989

Actavis Totowa LLC

IN-PROCESS TESTING (BLEND SAMPLE) TEST REPORT

Product: **Digoxin Tablets, USP 0.25 mg**			
MOI #: **145**	Revision #: **08**	Product ID #: **146**	**Page 1 of 1**
Prepared By: Tamsmin Murphy	Date: 03/19/07	Approved By: Talbot 03/27/07	Effective Date: 07/12/07

Batch # 70670A	Theoretical tablet weight: **120.0 mg**

TEST (Source)	**SPECIFICATION**	**RESULT**	**REFERENCE** Volume/Page/ Chemist/Date
Description (In-house):	White to off-white colored slug or free flowing powder	white to off-white free flowing powder	0102/22 AKP 08/16/07
Blend Uniformity (In-house):			0102/22 AKP 08/16/07
Center - Top		92.4 %	
Center - Middle		95.8 %	
Center - Bottom		97.0 %	
Left Slope		95.6 %	
Right Slope		95.1 %	
Left - Middle		94.5 %	
Left - Top		95.2 %	
Right - Middle		94.9 %	
Right - Top		97.8 %	
Front - Middle		94.2 %	
Average:	90.0% - 110.0%	95.2 %	
RSD:	NMT 5.0%	1.5 %	

(✓) COMPLIES	( ) DOES NOT COMPLY

Reviewed By: JCJ
Date: 08/21/07

DATA APPROVAL	
By:	Date: 08/22/07

PLAINTIFFS' EXHIBITS 000085

actavis

TOTOWA LLC

Laboratory Analysis Request Form

Name:	Digoxin Tablets USP 0.25mg
Identification #:	Prod ID # 146
Batch/PO/Lot #:	Batch # 70670A
Sample Type: (Specify interval, fill and conditions for stability samples)	Final Blend
Sample Size/Amount:	As per attached submission form
Testing Required:	☒ Per Product Specifications in process
	☐ Other (Specify):
Additional Information/ Comments:	N/A
Requested By:	DR — Date: 08/11/07 — Dept: QA

For QC Use Only			
Sample ID #:	0668		
Issued By:	CDP	Date:	08/11/07
Comments:	30 samples, of final Blends, consist of 3-sets.		

PLAINTIFFS' EXHIBITS 000086

ACTAVIS TOTOWA LLC

Id# 0668

QA SAMPLE SUBMISSION FORM

Item # N / A Item Name: N / A

IN – PROCESS / FINISHED PRODUCT:

MPR # 14602 - 10 Product : Digoxin Tablets, USP 0.25mg

Stage: Final Blend (Set: 1) Batch # 70670A

SAMPLE DESCRIPTION: Blender # 36

	TARE Wt.	GROSS Wt.	Net Wt:	
1 Center – Top	14978	15297	319	mg
2 Center – Middle	15058	15388	330	mg
3 Center – Bottom	14978	15307	335	mg
4 Left - Slope	15038	15355	317	mg
5 Right - Slope	15053	15350	297	mg
6 Left - Middle	14996	15285	289	mg
7 Left - Top	14962	15310	348	mg
8 Right – Middle	15070	15760	330	mg
9 Right – Top	15017	15302	285	mg
10 Front - Middle	14989	15275	286	mg

Theo. Wt: 120.0 mg

TESTING REQUIRED :

As per in process specification

Submitted BY : DR Date : 08/16/07

Submitted on 8/11/07

QA119.0

PLAINTIFFS' EXHIBITS 000087

ACTAVIS TOTOWA LLC

Id# 0668

QA SAMPLE SUBMISSION FORM

Item # N / A Item Name: N / A

IN – PROCESS / FINISHED PRODUCT:

MPR # 14602 - 10 Product : Digoxin Tablets, USP 0.25mg

Stage: Final Blend (Set: 2) Batch # 70670A

SAMPLE DESCRIPTION: Blender # 36

	TARE Wt.	GROSS Wt.	Net Wt:	
1 Center – Top	14994	15290	296	mg
2 Center – Middle	15069	15380	311	mg
3 Center – Bottom	15173	15473	300	mg
4 Left - Slope	15047	15360	313	mg
5 Right - Slope	15030	15340	310	mg
6 Left - Middle	15010	15291	281	mg
7 Left - Top	15054	15333	279	mg
8 Right – Middle	14994	15308	314	mg
9 Right – Top	15022	15314	292	mg
10 Front - Middle	15024	15324	300	mg

Sample not tested

JCS

08/21/07

Theo. Wt: 120.0 mg

TESTING REQUIRED :

As per in process specification

Submitted BY : Date : 08/10/07

Submitted on 8/11/07

QA119.0

ACTAVIS TOTOWA LLC

Id# 0668

QA SAMPLE SUBMISSION FORM

Item # N / A Item Name: N / A

IN – PROCESS / FINISHED PRODUCT:

MPR # 14602 - 10 Product : Digoxin Tablets, USP 0.25mg

Stage: Final Blend **(Set: 3)** Batch # 70670A

SAMPLE DESCRIPTION: Blender # 36

	TARE Wt.	GROSS Wt.	Net Wt:	
1 Center – Top	15144	15450	306	mg
2 Center – Middle	15026	15323	297	mg
3 Center – Bottom	15103	15405	302	mg
4 Left - Slope	14968	15265	297	mg
5 Right - Slope	15083	15392	309	mg
6 Left - Middle	15028	15333	305	mg
7 Left - Top	15030	15329	299	mg
8 Right – Middle	14997	15328	331	mg
9 Right – Top	15087	15380	293	mg
10 Front - Middle	14943	15280	337	mg

Sample not tested
JCS
08/21/07

Theo. Wt: 120.0 mg

TESTING REQUIRED :

As per in process specification

Submitted BY : DR Date : 08/10/07

Submitted on 8/10/07

QA119.0

PLAINTIFFS' EXHIBITS 000089

Actavis Totowa LLC Department Operating Instruction

TITLE: **Evaluation of Laboratory Error**		
DOI: **QC-106**	Revision: **04**	**ATTACHMENT**

LABORATORY ERROR EVALUATION REPORT

Product: Digoxin Tablets, 0.25 mg, USP			Batch/Lot: 70670A
Laboratory Error Number: **LEN 07- 065**			Date Initiated: 08/17/07
Test: Blend Uniformity		MOI/Method: # 145	Rev: # 08
Date Incident Occurred: 08/17/07		Sample: Final Blend (i.e., raw material, in-process, finished product, stability with time/conditions, etc.)	
Instrument ID: HPLC# 14			
Analyst: AKP	Date: 08/17/07	Book: 0102	Page: 22

Background:

Analyst was performing blend uniformity test for above batch using MOI# 145, REV# 08. Analyst selected wrong TotalChrom method and sequence for HPLC testing. MOI# 145 having two different methods. For Digoxin Tablets 0.125 mg method ID# 145 and Digoxin Tablets 0.25 mg method ID# 146. Testing was performed according to method ID# 146 and found the results within product specification. Analyst misinterpreted MOI to select the TotalChrom template for method and sequence, instead of ID# 146 template analyst selected ID# 145.

Action:

Analyst was instructed to calculate the results using Quattro-pro program and compare the results obtained from TotalChrom software.

Conclusion:

The results using Quattro-pro program and TotalChrom software were the same and are within product Specifications.

Analyst: AKP Date: 08/21/07 Supervisor: [signature] Date: 08/21/07

Approval: ☑ Evaluation is completed.

QC Director: [signature] Date: 08/22/07

PLAINTIFFS' EXHIBITS 000090